The article you requested is
Novel Use of Tramadol Hydrochloride in the Treatment of Tourette’s Syndrome
J Clin Psychiatry 1997;58:174-175 [letter]
Copyright 1997 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
Purchase this PDF for $30
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($129) or print + online ($166 individual).
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email
Letter to the Editor
Sir: Studies have demonstrated that symptoms of Tourette’s
syndrome can be attenuated by modulation of the opioid system.
However, the response to opioid agonists or antagonists
is often limited by side effects and the development of tolerance.
Additionally, these compounds have significant abuse potential.
The opioid tramadol hydrochloride (Ultram) has low abuse potential,
low physical dependency, and mild tolerance. It binds to
opioid receptors and also inhibits the reuptake of norepinephrine
and serotonin. We report the successful use of tramadol in the
treatment of a patient with severe Tourette’s syndrome.